Novartis' Afinitor wins EU approval for breast cancer
This article was originally published in Scrip
Executive Summary
The European Commission has approved Novartis' Afinitor (everolimus) to treat advanced breast cancer in combination with Pfizer's Aromasin (exemestane). The commission has granted approval in all 27 EU member states, Norway and Iceland.